Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc (BRNS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
brns · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.00
Consensus
$3.00
+331.7% upside
Low
$3.00
Median: $3 · Last Close: $0.69
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.70 | ↑ 0.76% |
1-day model range: $0.7–$0.71. Peak: $0.71 (+0.76%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -49.5% |
| 2028 | $0 | -62.0% |
| 2029 | $0 | -66.7% |
| 2030 | $0 | -68.7% |
| 2031 | — | -69.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BRNS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-09-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-13 | Alliance Global Partners | Maintains | Buy→Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-13 | Barclays | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Barinthus Biotherapeutics plc (BRNS) stock. Of the recent 26 rating actions, 0 were upgrades and 1 were downgrades. 4 analysts currently cover BRNS.
Analyst Recommendation Trends
BRNS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↑ 62.0% YoY
Revenue Next Year
$10M
↑ 1132.0% YoY
EPS This Year
$-2.02
EPS Next Year
$-1.48
↓ 27.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast BRNS EPS of $-2.02 for the current fiscal year, based on estimates from 5 analysts. The BRNS revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BRNS stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BRNS price target is $3.00 (+331.7% upside), with an analyst consensus of Buy.
The BRNS short-term stock prediction for tomorrow is $0.70 (+0.76%). The BRNS stock price prediction for 2027 estimates an average of $0. The BRNS stock prediction for 2030 projects a range of $0–$0.
Barinthus Biotherapeutics plc trades on NASDAQ under the ticker BRNS. The BRNS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
BRNS forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month BRNS price target is $3.00, with a high forecast of $3.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +331.7% potential upside from the current price of $0.69.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.